High rates of midazolam injection among drug users in Bangkok, Thailand by Kerr, Thomas et al.
RESEARCH Open Access
High rates of midazolam injection among drug












Background: Reports from Thailand suggest that a growing number of people who inject drugs (IDU) are now
injecting midazolam, a legal benzodiazepine with potent amnestic and ventilatory depressant effects. We therefore
sought to examine midazolam injection among a community-recruited sample of Thai IDU.
Methods: We examined the prevalence and correlates of midazolam injection among 252 IDU participating in the
Mitsampan Community Research Project, Bangkok, using multivariate logistic regression. We also examined the use
of midazolam in combination with other drugs.
Results: 252 IDU participated in this study, including 66 (26.2%) women. In total, 170 (67.5%) participants reported
ever having injected midazolam, and 144 (57.1%) reported daily midazolam injection in the past six months. In
multivariate analyses, a history of midazolam injection was independently associated with using drugs in
combination (adjusted odds ratio [AOR] = 5.86; 95% confidence interval [CI]: 2.96-11.60), younger age (AOR = 0.43;
95%CI: 0.22-0.83), having a history of methadone treatment (AOR = 3.12, 95%CI: 1.55-6.90), and binge drug use
(AOR = 2.25, 95%CI: 1.09-4.63). The drugs most commonly used in combination with midazolam were heroin
(72.3%) and yaba (methamphetamine) (30.5%).
Conclusion: We observed a high rate of midazolam injection among Thai IDU. Midazolam injection was strongly
associated with polysubstance use and binge drug use, and was most commonly used in combination with both
opiates and methamphetamines. Our findings suggest that midazolam injection has become increasingly common
within Thailand. Evidence-based approaches for reducing harms associated with midazolam injection are needed.
Background
Thailand, like many other countries globally has been
experiencing shifting patterns of drug supply and use
[1-7]. Studies undertaken during the past decade suggest
a number of Thai people who inject drugs (IDU) are
now injecting midazolam (Thai trade name: Dormi-
cum®), a legal, rapid onset, short duration benzodiaze-
pine with potent sedative, amnestic and ventilatory
depressant effects [8-10]. Midazolam is prescribed in
tablet form, although it is often administered intrave-
nously for sedation in hospital settings [9]. However, it
has been reported anecdotally that some Thai physicians
also prescribe midazolam for the treatment of withdra-
wal from opiate use [11]. A study indicated rising
midazolam injection among Thai IDU, with 30% of an
IDU sample reporting midazolam injection during 1999-
2000 [9]. This trend was believed to coincide with the
Thai government’s increasing focus on drug enforce-
ment and the declining availability and rising price of
heroin in Thailand. Midazolam is much less expensive
(approximately $3 USD per tablet) to acquire than her-
oin [8].
It has been suggested that midazolam injection, partly
because of the associated amnestic effects, can result in
elevated rates of risk behaviour, including syringe shar-
ing [9]. The injection of midazolam filtrate is believed to
increase risk for soft-tissue infections, gangrene, and
thromboembolic events [8]. Withdrawal effects are typi-
cal of benzodiazepines and include headaches, insomnia,
agitation and seizures and can be fatal [8]. Further, con-
cerns have been expressed regarding high rates of poly-
substance use among IDU who inject midazolam,
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tion [9]. Given these concerns, the ongoing “drug war”
in Thailand, and the paucity of research on midazolam
use, we sought to examine the prevalence and correlates
of midazolam injection, as well as patterns of midazo-
lam-related polysubstance use, among a community-
recruited sample of IDU in Bangkok, Thailand.
Methods
The Mitsampan Community Research Project is a colla-
borative research project involving the British Columbia
Centre for Excellence in HIV/AIDS (Vancouver,
Canada), the Mitsampan Harm Reduction Center (Bang-
kok, Thailand), the Thai AIDS Treatment Action Group
(Bangkok, Thailand), and Chulalongkorn University
(Bangkok, Thailand). During July-August 2008, the part-
ners undertook a cross-sectional study involving 252
community-recruited IDU. The primary aims of the
study were to assess drug use and HIV risk behaviors
and to assess barriers to access to healthcare among
local IDU. Potential participants were recruited through
peer-based outreach efforts and word of mouth. Study
participants were invited to attend the Mitsampan Harm
Reduction Center (MSHRC) to participate in the study.
The Mitsampan Center was established in the Mitsam-
pan neighborhood, which is home to large number of
illicit drug users and low-income residents. Individuals
were eligible for participation in this study and defined
as an “IDU” if they reported injection of illicit drugs in
the past six months. All participants provided informed
consent and completed an interviewer-administered
questionnaire eliciting information about demographic
characteristics, drug use, HIV risk behaviour, criminal
justice system exposure, and experiences with health
care. All participants were given 250 Baht (approxi-
mately $7 USD) upon completion of the questionnaire.
The study has been approved by the Research Ethics
Boards of the University of British Columbia and Chula-
longkorn University.
Using univariate statistics and multivariate logistic
regression, we compared IDU who did and did not
report a history of midazolam injection. Variables con-
sidered included: median age (< 36.5 years or ≥ 36.5
years), gender, education level (< secondary school vs. ≥
secondary school), heroin injection (yes vs. no), yaba
(i.e., methamphetamine) injection (yes vs. no), use of
drugs in combination (yes vs. no), syringe borrowing
(yes vs. no), syringe lending (yes vs. no), non-fatal over-
dose (yes vs. no), binge drug use (yes vs. no), having
had drugs planted on oneself by police (yes vs. no),
incarceration (yes vs. no), compulsory treatment experi-
ence (yes vs. no), and methadone treatment (yes vs. no).
Use of drugs in combination refers to use of more than
one drug at the same time (i.e., not the simple use of
two drugs in the same day or week). We considered
experiences of drug planting by police given that this
type of contact with police could potentially prompt
some IDU to obtain midazolam, given that the drug can
be obtained “over-the-counter” in selected pharmacies
and acquiring it may involve little or no contact with
the illicit drug market. This variable was ascertained by
asking participants “Have police ever planted drugs on
you?” Binge drug use refers to periods when drugs are
used more often than usual. All behavioural variables
refer to lifetime history (e.g., ever injected yaba). To
examine the bivariate associations, we used the Pearson
c
2 test. We then examined factors independently asso-
ciated with a history of midazolam injection use by fit-
ting a multivariate logistic regression model that
included all variables that were associated with midazo-
lam injection at the p ≤ 0.05 level in univariate analyses.
All p-values were two-sided. We also asked participants
who reported midazolam injection about the frequency
of their midazolam injecting in the previous six months,
and the drugs they used (if any) in combination with
midazolam.
Results
In total, 252 IDU participated in this study, including 66
(26.2%) females. The median age of participants was
36.5 years. Two hundred and thirty-eight (94.4%) parti-
cipants were born in the Bangkok Metropolitan Area. In
total, 170 (67.5%) participants reported that they had
injected midazolam previously and, of these, 144 (81.4%,
57% of the total sample) reported daily midazolam injec-
tion in the past six months. As indicated in Table 1, in
univariate analyses, factors positively associated with
MSHRC use included use of drugs in combination
(odds ratio [OR] = 7.53, 95% confidence interval [CI]:
4.14-13.71), syringe borrowing (OR = 1.94, 95%CI: 1.08-
3.47), having drugs planted on oneself by police (OR =
3.03, 95%CI: 1.73-5.30), incarceration (OR = 2.05, 95%
CI: 1.11-3.78), methadone treatment (OR = 4.29, 95%CI:
2.35-7.86), and binge drug use (OR = 2.90, 95%CI: 1.60-
5.26). Younger age (OR = 0.52, 95%CI: 0.30-0.89) and
female gender (OR = 0.43, 95%CI: 0.24-0.76) were nega-
tively associated with midazolam injection. As indicated
in Table 2, in multivariate analyses, midazolam injection
was positively associated with use of drugs in combina-
tion (adjusted odds ratio [AOR] = 5.86; 95%CI: 2.96-
11.60), binge drug use (AOR = 2.25; 95%CI: 1.09-4.63),
methadone treatment (AOR = 3.12; 95%CI: 1.55-6.90),
and was negatively associated with younger age (AOR =
0.43; 95%CI: 0.22-0.83). Among midazolam injectors,
65% reported using drugs in combination with other
substances, with the substances most commonly used in
combination with midazolam being heroin (72.3%), yaba
(30.5%), methadone (7.6%), and alcohol (4.7%).
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In the present study, we found that approximately 68% of
a community-recruited sample of IDU in Bangkok had
injected midazolam previously. Fifty-seven percent of the
sample had injected midazolam at least once a day in the
past six months. Midazolam injectors were more likely to
report using drugs in combination, binge drug use, and a
history of methadone treatment. Midazolam injectors
tended to be older, and were less likely to be female.
Sixty-five percent of midazolam injectors reported use of
drugs in combination, with heroin and yaba being the
drugs most commonly used with midazolam.







Odds Ratio (95% CI) p value
Median age
< 36.5 years 76 (45) 50 (61) 0.52 (0.30 - 0.89) 0.02
≥ 36.5 years 94 (55) 32 (39)
Gender
female 35 (21) 31 (38) 0.43 (0.24 - 0.76) < 0.01
male 135 (79) 51 (62)
Education
≥ secondary 106 (62) 43 (52) 1.50 (0.88 - 2.56) 0.14
< secondary 64 (38) 39 (48)
Ever injected heroin
yes 161 (95) 73 (89) 2.21 (0.84 - 5.79) 0.11
no 9 (5) 9 (11)
Ever injected yaba (methamphetamine)
Yes 109 (64) 52 (63) 1.03 (0.60 - 1.78) 0.91
no 61 (36) 30 (37)
Ever used drugs in combination
yes 142 (84) 33 (40) 7.53 (4.14 - 13.71) <0.01
no 28 (16) 49 (60)
Binge drug use
yes 80 (47) 19 (24) 2.90 (1.60 - 5.26) < 0.01
no 90 (53) 62 (76)
Ever borrowed used syringes
yes 68 (40) 21 (26) 1.94 (1.08 - 3.47) 0.03
no 102 (60) 61 (74)
Ever lent used syringes
yes 62 (36) 30 (37) 1.00 (0.58 - 1.72) 0.99
no 108 (64) 52 (63)
Ever overdosed
yes 59 (35) 16 (20) 2.19 (1.17 - 4.12) 0.02
no 111 (65) 66 (80)
Ever had drugs planted on you by police
yes 97 (57) 25 (30) 3.03 (1.73 - 5.30) <0.01
no 73 (43) 57 (70)
Ever been in prison
yes 140 (82) 57 (70) 2.05 (1.11 - 3.78) 0.02
no 30 (18) 25 (30)
Ever been in forced drug treatment
yes 56 (33) 24 (29) 1.19 (0.67 - 2.11) 0.56
no 114 (67) 58 (71)
Ever on methadone treatment
yes 93 (55) 18 (22) 4.29 (2.35 - 7.86) <0.01
no 77 (45) 64 (78)
Kerr et al. Harm Reduction Journal 2010, 7:7
http://www.harmreductionjournal.com/content/7/1/7
Page 3 of 6The prevalence of midazalom injection found in the
present study is much higher than most previously
reported rates [9,12]. Van Griensven et al. reported a rise
in self-reported midazolam injection in the previous six
months, from approximately 10% in 1999 to 30% in 2000
[9], and a report from 2005 found that 73% of IDU in
Bangkok had a history of midazolam injection [13]. How-
ever, while approximately 16% of the total sample in the
latter study reported injecting midazolam on a daily basis
in the previous month, 57% of IDU participating in our
study said they injected the drug on a daily basis in the
previous six months. Collectively these findings suggest
that the prevalence, and more notably the intensity of
midazolam injection have continued to increase steadily
since 1999. It is believed that midazolam is often used as
a cheaper and more accessible alternative to heroin, par-
ticularly when heroin availability declines and heroin
price increases [8,9]. Previous studies have indicated that
the prevalence of midazolam injecting increased follow-
ing the initiation of Thailand’s “War on Drugs” in Febru-
ary 2003 [7,14]. This initiative involved scaling up efforts
to seize drugs, arrest drug dealers, and force drug users
into military-style boot camps [7]. It has been reported
that over 2,200 suspected drug dealers were killed via
extrajudicial execution during its implementation [15].
The precise role of Thailand’s drug war on the drug pat-
terns observed herein is difficult to determine. However,
previous studies have found that transitions in injection
drug use as well as an initiation of, or increase in, misuse
of more licit drugs may occur among drug using popula-
tions exposed to an increase in drug enforcement [16,17].
Midazolam injection was strongly associated with the
use of drugs in combination and was reportedly most
commonly used in combination with both heroin and
methamphetamine. This raises concern regarding the
potential elevated risk for overdose as a result of poly-
substance use [18]; however, it is notable that while
midazolam was associated with non-fatal overdose, this
association did not persist in a multivariate analysis.
Midazolam injection was also associated with binge
drug use, which is concerning given that binge drug use
has been associated with HIV infection among IDU
[19]. Although concern has been expressed regarding
the impact of midazolam injection on syringe sharing
[9], in particular as a result of the amnestic effects of
the drug, the association between syringe borrowing and
midazolam injection also did not persist in our multi-
variate analysis.
The findings of this study have implications for harm
reduction practice. First, because midazolam filtrate is
highly acidic and damaging to veins, midazolam injec-
tors are known to resort to groin injection when periph-
eral veins are no longer usable. Groin injection carries
significant risk, including risk for deep vein thrombosis,
pulmonary embolus, abscesses, and puncture of the
femoral artery, vein, or nerve [20]. Therefore established
harm reduction approaches specific to groin injecting
should be applied in work with midazolam injectors
[20], including encouraging midazolam injectors to
avoid initiating groin injecting by exercising proper vein
care to maintain peripheral veins, or by switching to an
alternate route of drug consumption when peripheral
Table 2 Multivariate logistic regression analysis of factors associated with a history of midazolam injection in MSCRP
cohort (n = 252)
Variable Adjusted Odds Ratio (AOR) 95% Confidence Interval (CI) p - value
Median age
(< 36.5 years vs. ≥ 36.5 years) 0.43 (0.22 - 0.83) 0.01
Gender
(female vs. male) 0.61 (0.29 - 1.3) 0.18
Binge drug use
(yes vs. no) 2.25 (1.09 - 4.63) 0.03
Ever used drugs in combination
(yes vs. no) 5.86 (2.96 - 11.60) < 0.01
Ever borrowed used syringes
(yes vs. no) 1.30 (0.64 - 2.65) 0.48
Ever overdosed
(yes vs. no) 1.23 (0.55 - 2.78) 0.62
Ever had drugs planted on you by police
(yes vs. no) 1.95 (0.95 - 3.98) 0.07
Ever been in prison
(yes vs. no) 1.40 (0.59 - 6.27) 0.48
Ever on methadone treatment
(yes vs. no) 3.12 (1.55 - 6.90) < 0.01
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Second, given that midazolam injectors frequently
experience abscesses and other soft-tissue infections,
efforts should be made to ensure early and appropriate
care for such infections. This may require providing
access to low-threshold care for soft-tissue infections.
Third, given the lack of access to sterile injecting sup-
plies in Thailand [21], efforts should be made to provide
midazolam injectors with appropriate injecting supplies,
including syringes and alcohol swabs. Lastly, because of
the amnesic effects of midazolam and the risks asso-
ciated with binge and combination drug use among
midazolam injectors, educational efforts should include
encouraging midazolam injectors to avoid injecting mid-
azolam when alone.
This study has limitations. Previous studies have indi-
cated that the majority of midazolam is distributed in
Bangkok [11], and the rates of midazolam injection
reported here may not generalize to other settings in
Thailand. As well, the data pertaining to midazolam
injection in Thailand is limited, and therefore conclu-
sions concerning changes in the prevalence of midazo-
lam injection should be interpreted with caution. This
points further to the outstanding need for more sys-
tematic surveillance of drug use trends in Thailand, as
well as data on the harms of illicit drug use, including
midazolam injection. Further, the study sample was not
randomly selected and therefore may not be representa-
tive of local IDU. We should also note that we relied on
self-report, and therefore our data may have been
affected by socially desirable responding or recall bias.
Finally, we identified a number of associations with mid-
azolam injecting, such as syringe sharing, which did not
persist in multivariate analyses. Because of the limited
sample size in our study, future research will be
required before we can conclude that midazolam injec-
tion is not associated with elevated risk behaviour.
In summary, we found extremely high rates of mida-
zolam injection among a cohort of Thai IDU in Bang-
kok. Midazolam injection was strongly associated with
the use of various drugs in combination and binge drug
use. Given the many adverse effects of midazolam injec-
tion, evidence-based pubic health interventions are
urgently needed to reduce the harms associated with
this form of drug use.
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